Search published articles


Showing 2 results for Sheikh Arabi
Changes in Blood Lipids and Enzymatic Reactions in Response to Atorvastatin Administration Following a High-Fat Diet in a NAFLD Rat Model
Zahra Eslami, Yahya Mohammadnajad Panah Kandi, Alireza Norouzi, Abdorreza Eghbal Moghanlou, Mehdi Sheikh Arabi, Vahideh Kazeminejad, Seyedeh Somayeh Hosseini Alarzi, Aref Saeidi, Hamidreza Joshaghani,
Volume 16, Issue 3 (May-Jun 2022)
Abstract
Background and objectives: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease caused by the accumulation of large amounts of fat in the hepatocytes. Given that atorvastatin is effective for treatment of NAFLD, the present study investigated effects of high-fat/fructose diet (HFFD) with atorvastatin on liver enzymes and lipid profile in a NAFLD rat model.
Methods: Thirty-two male Wistar rats were divided into four groups: 1) normal control, 2) HFFD control, 3) HFFD + atorvastatin, and 4) normal + atorvastatin. The groups received HFFD for 15 weeks to induce hepatosteatosis. Atorvastatin was administrated at the dose of 10 mg/kg/day. Lipid profile and liver enzymes were measured after eight weeks of intervention.
Results: Triglyceride, cholesterol, gamma-glutamyl transferase, and aspartate transaminase were significantly reduced in the HFFD + atorvastatin group compared with the HFFD control group. In addition, cholesterol, high-density lipoprotein, alkaline phosphatase, and gamma-glutamyl transferase were significantly increased in the normal + atorvastatin group compared with the normal control group. Low-density lipoprotein increased significantly in the HFFD + atorvastatin group and the normal + atorvastatin group compared with other groups. There was a significant difference in the alanine transaminase levels between the groups taking atorvastatin. In fact, alanine transaminase level was lowest in the normal + atorvastatin group.
Conclusion: Atorvastatin improves the lipid profile and fatty liver and controls liver enzymes. Therefore, it can be used with caution to improve the lipid profile and reduce the complications of NAFLD.
Investigating the relationship between serum zinc levels and red blood cell indices in anemic patients referred to the laboratories in Gorgan, Iran
Zahra Eslami , Shayan Marhamaty, Seyyed Mehdi Jafari , Mohadese Khorasani , Mehdi Sheikh Arabi , Hamidreza Joshaghani ,
Volume 19, Issue 1 (4-2025)
Abstract
Background: Bivalent minerals function as crucial cofactors that participate in a multitude of metabolic pathways within the organism. Specifically, zinc (Zn) assumes catalytic, structural, and regulatory roles in numerous biological processes. A severe deficiency in Zn can lead to disruptions in nucleic acid and protein synthesis, impaired cellular proliferation, increased apoptosis, and heightened lipid peroxidation of cellular membranes, a phenomenon associated with a reduced lifespan of red blood cells (RBCs). The objective of this study was to investigate the correlations between Zn status and various erythrocyte indices in a cohort of anemic patients, in comparison to a control group.
Methods: A cohort of 563 participants was enrolled in this investigation. Serum Zn concentration was quantified using a BT-3500 autoanalyzer, while hematological indices were determined via a Sysmex KX21N cell counter. Following confirmation of data normality, Spearman's rank correlation coefficient was employed to analyze the relationship between serum Zn levels and RBC indices.
Results: The mean serum Zn concentration was 102.8 ± 17.6 mg/dL. Serum Zn levels exhibited a weak correlation with RBC and hemoglobin (Hb) concentrations in healthy women, as well as a weak correlation with mean corpuscular hemoglobin concentration (MCHC) in anemic men (p < 0.05). Furthermore, the results indicated significantly higher serum Zn levels, RBC, Hb, hematocrite (HCT), and MCHC in men (p < 0.01), while mean corpuscular volume (MCV) was significantly higher in women (p < 0.01). Notably, in individuals with serum Zn levels < 30 mg/dL, MCHC (p < 0.01) and RBC (p < 0.05) were elevated, whereas Hb (p < 0.05), HCT, MCV, and MCH (p < 0.01) were higher than 30.
Conclusion: Considering the potential impact of varying Zn concentrations on erythrocyte indices, including Hb and MCHC, in both healthy and anemic individuals, careful regulation of its dosage is warranted.
 

Page 1 from 1     

© 2007 All Rights Reserved | Medical Laboratory Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.